Saul Yedgar
Corporate Officer/Principal bij The Hebrew University of Jerusalem
Profiel
Saul Yedgar is a Professor-Emeritus at The Hebrew University of Jerusalem, where he has been employed since 1982.
He previously worked as the Chief Scientific Officer at Celsus Therapeutics Plc from 2005 to 2011.
Prior to that, he held positions as a Principal at the National Institutes of Health and Institut Curie.
Yedgar received his undergraduate degree from Bar-Ilan University and his doctorate from The Hebrew University of Jerusalem in 1977.
Actieve functies van Saul Yedgar
| Bedrijven | Functie | Begin |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | 01-01-1982 |
Eerdere bekende functies van Saul Yedgar
| Bedrijven | Functie | Einde |
|---|---|---|
Institut Curie
 Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Saul Yedgar
| The Hebrew University of Jerusalem | Doctorate Degree |
| Bar-Ilan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Institut Curie
Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Commercial Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
